GW Pharma, armed with best-case DEA decision, charts path to Epidiolex launch

GW Pharmaceuticals won historic FDA approval back in June when the agency green-lighted its cannabidiol drug Epidiolex to treat rare and severe forms of epilepsy. But the new medication has been stuck in the starting gate, waiting for the Drug Enforcement Administration to decide how to handle the first-of-its kind drug.